Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein

Ekaterina O. Serebrovskaya, Eveline F. Edelweiss, Oleg A. Stremovskiy, Konstantin A. Lukyanov, Dmitry M. Chudakov, Sergey M. Deyev

Research output: Contribution to journalArticlepeer-review

122 Citations (Scopus)


Antibody-photosensitizer chemical conjugates are used successfully to kill cancer cells in photodynamic therapy. However, chemical conjugation of photosensitizers presents several limitations, such as poor reproducibility, aggregation, and free photosensitizer impurities. Here, we report a fully genetically encoded immuno-photosensitizer, consisting of a specific anti-p185HER-2-ECD antibody fragment 4D5scFv fused with the phototoxic fluorescent protein KillerRed. Both parts of the recombinant protein preserved their functional properties: high affinity to antigen and light activation of sensitizer. 4D5scFv-KillerRed showed fine targeting properties and efficiently killed p185HER-2-ECD-expressing cancer cells upon light irradiation. It also showed a remarkable additive effect with the commonly used antitumor agent cisplatin, further demonstrating the potential of the approach.

Original languageEnglish
Pages (from-to)9221-9225
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number23
Publication statusPublished - 9 Jun 2009
Externally publishedYes


  • KillerRed
  • Phototoxicity
  • Reactive oxygen species


Dive into the research topics of 'Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein'. Together they form a unique fingerprint.

Cite this